Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 1/20 | 0.47 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.43 |
| ▸ | BTK | Q06187 | 2/20 | 0.42 |
| ▸ | JAK3 | P52333 | 1/20 | 0.42 |
| ▸ | PIM2 | Q9P1W9 | 12/20 | 0.42 |
| ▸ | PIM3 | Q86V86 | 9/20 | 0.42 |
| ▸ | PIM1 | P11309 | 8/20 | 0.42 |
| ▸ | KIF18A | Q8NI77 | 1/20 | 0.42 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.40 |
| ▸ | SYK | P43405 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13028164 | 1.00 | CHEK1 (0.47) | CHEK1PDE10ABTKJAK3PIM2 | |
| SCHEMBL13028160 | 0.93 | BTK (0.45) | CHEK1PDE10ABTKJAK3PIM2 | |
| SCHEMBL13028165 | 0.93 | BTK (0.45) | CHEK1PDE10ABTKJAK3PIM2 | |
| SCHEMBL4438374 | 0.84 | BTK (0.46) | PDE10ABTKJAK3PIM2PIM3 | |
| SCHEMBL4438377 | 0.84 | BTK (0.46) | PDE10ABTKJAK3PIM2PIM3 | |
| SCHEMBL13027520 | 0.84 | PIM2 (0.59) | CHEK1PIM2PIM3PIM1 | |
| SCHEMBL13027503 | 0.84 | PIM2 (0.59) | CHEK1PIM2PIM3PIM1 | |
| SCHEMBL11907983 | 0.79 | PIM2 (0.48) | BTKJAK3PIM2PIM3PIM1 | |
| SCHEMBL11907982 | 0.79 | PIM2 (0.48) | BTKJAK3PIM2PIM3PIM1 | |
| SCHEMBL2693948 | 0.78 | PIM3 (0.54) | CHEK1BTKJAK3PIM2PIM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8293747-B2 | Heterocyclic amide compounds as protein kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2012-10-23 | — | — | US | disclosed |
| US-8293747-B2 | Heterocyclic amide compounds as protein kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2012-10-23 | — | — | US | disclosed |
| US-20100286135-A1 | HETEROCYCLIC AMIDE COMPOUNDS AS PROTEIN KINASE INHIBITORS | Schering Corporation Patent Department, K-6-1; 1990 (US) | 2010-11-11 | — | — | US | disclosed |
| US-20100286135-A1 | HETEROCYCLIC AMIDE COMPOUNDS AS PROTEIN KINASE INHIBITORS | Schering Corporation Patent Department, K-6-1; 1990 (US) | 2010-11-11 | — | — | US | disclosed |
| WO-2009014637-A2 | HETEROCYCLIC AMIDE COMPOUNDS AS PROTEIN KINASE INHIBITORS | SCHERING CORPORATION (US) | 2009-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286135-A1 | HETEROCYCLIC AMIDE COMPOUNDS AS PROTEIN KINASE INHIBITORS | MTOR, CDK1, MAP3K8 | CHEK1 113/4885PDE10A 1787/4885BTK 589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.